Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More Checks And Balances For Orphan Drugs Needed, Says Germany’s G-BA

Executive Summary

The German pricing and reimbursement authority wants better scrutiny of orphan drug designations and incentives for orphan drug development to help address the access problem.

You may also be interested in...

Interview: Eucope On Turning Ten, Defending Orphan Incentives And Securing Market Access For Cell And Gene Therapies

Ten years on from its inception, the European Confederation of Pharmaceutical Entrepreneurs is focused on defending the incentives system for developing orphan drugs.

EU Orphan Designations Fall Sharply In 2017

The number of medicines awarded orphan designation in the EU has fallen for the first time since 2013. In 2017 there were 144, considerably fewer than in 2016 when there were 209. In the meantime, orphan drug advocacy group Eurordis says radical change is needed if patients are to have broader access to these important but often highly priced drugs.

Lessons From Europe: Orphan Drug Valuations Show Limits Of Cost Effectiveness

Biogen, Sanofi executives says US should learn from experience of European health technology assessment bodies as Institute for Clinical and Economic Review embarks on initiative to adapt its value framework to orphan drugs.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts